Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications
Gaia Griguolo(University of North Carolina at Chapel Hill), Valentina Guarneri(Istituto Oncologico Veneto), Federica Miglietta(University of Padua), Grazia Maria Vernaci(University of Padua), Michele Bottosso(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto)
Cited by 42
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226